Bio-Rad Laboratories Inc $ 509.78 7.93 (1.58%)
Volume:
170,450
Avg Vol (1m):
294,024
Market Cap $:
15.16 Bil
Enterprise Value $:
14.77 Bil
P/E (TTM):
7.90
P/B:
2.06
Financial Strength | 8/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 1.6 | ||
| Equity-to-Asset | 0.73 | ||
| Debt-to-Equity | 0.09 | ||
| Debt-to-EBITDA | 0.24 | ||
| Interest Coverage | 10.55 | ||
| Piotroski F-Score | 6 | ||
| Altman Z-Score | 5.45 | ||
| Beneish M-Score | -2.74 | ||
| WACC vs ROIC | |||
Profitability Rank | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 10.59 | ||
| Net Margin % | 84.89 | ||
| ROE % | 32.43 | ||
| ROA % | 23.39 | ||
| ROC (Joel Greenblatt) % | 187.69 | ||
| 3-Year Revenue Growth Rate | 3.2 | ||
| 3-Year EBITDA Growth Rate | 125.3 | ||
| 3-Year EPS without NRI Growth Rate | 304.6 |
Valuation Rank | 2/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 7.78 | ||
| PE Ratio without NRI | 7.78 | ||
| Price-to-Owner-Earnings | 5.91 | ||
| PB Ratio | 2.04 | ||
| PS Ratio | 6.6 | ||
| Price-to-Free-Cash-Flow | 46.98 | ||
| Price-to-Operating-Cash-Flow | 36.49 | ||
| EV-to-EBIT | 5.75 | ||
| EV-to-EBITDA | 5.46 | ||
| EV-to-Revenue | 6.35 | ||
| PEG Ratio | 0.18 | ||
| Shiller PE Ratio | 31.53 | ||
| Current Ratio | 2.3 | ||
| Quick Ratio | 1.62 | ||
| Days Inventory | 203.64 | ||
| Days Sales Outstanding | 57.43 | ||
| Days Payable | 45.69 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.4 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 2.18 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 2.1 | ||
| Price-to-Median-PS-Value | 3.41 | ||
| Price-to-Peter-Lynch-Fair-Value | 0.31 | ||
| Price-to-Graham-Number | 0.87 | ||
| Earnings Yield (Greenblatt) % | 17.4 | ||
| Forward Rate of Return (Yacktman) % | 20.97 |